{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:15:19Z","timestamp":1758046519695,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ando.2022.12.424","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T11:53:56Z","timestamp":1674215636000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates in neuroendocrine neoplasms: From mechanisms to the clinic"],"prefix":"10.1016","volume":"84","author":[{"given":"Sarah","family":"Fodil-Cherif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Desailloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2022.12.424_bib0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ando.2022.12.424_bib0285","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ando.2022.12.424_bib0290","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ando.2022.12.424_bib0295","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s43588-021-00086-z","article-title":"Undisclosed, unmet and neglected challenges in multi-omics studies","volume":"1","author":"Tarazona","year":"2021","journal-title":"Nat Comput Sci"},{"key":"10.1016\/j.ando.2022.12.424_bib0300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ando.2022.12.424_bib0305","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1126\/science.1204040","article-title":"Exploring the genomes of cancer cells: progress and promise","volume":"331","author":"Stratton","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ando.2022.12.424_bib0310","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ando.2022.12.424_bib0315","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ando.2022.12.424_bib0320","article-title":"Genomics of adrenocortical tumors: from molecular classification to identification of driver genes","author":"Jouinot","year":"2022","journal-title":"Present Soc Endocrinol"},{"key":"10.1016\/j.ando.2022.12.424_bib0325","first-page":"381","article-title":"A metastatic ACC mouse model: combined inactivation of Znrf3 & Tp53 results in consistent adrenocortical carcinoma formation","volume":"81","author":"Wilmouth","year":"2022","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ando.2022.12.424_bib0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ando.2022.12.424_bib0335","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2022.12.424_bib0340","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2022.12.424_bib0345","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1210\/jc.2017-01401","article-title":"Corticotroph pituitary carcinoma in a patient with lynch syndrome (LS) and pituitary tumors in a nationwide LS Cohort","volume":"102","author":"Bengtsson","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0350","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1507\/endocrj.EJ17-0036","article-title":"Atypical pituitary adenoma with MEN1 somatic mutation associated with abnormalities of DNA mismatch repair genes; MLH1 germline mutation and MSH6 somatic mutation","volume":"64","author":"Uraki","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2022.12.424_bib0355","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cancergen.2021.03.008","article-title":"Invasive ACTH-producing pituitary gland neoplasm secondary to MSH2 mutation","volume":"256","author":"Loughrey","year":"2021","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ando.2022.12.424_bib0360","first-page":"1","article-title":"Aggressive pituitary adenoma in the context of Lynch syndrome: a case report and literature review on this rare coincidence","volume":"35","author":"Teuber","year":"2021","journal-title":"Br J. Neurosurg"},{"key":"10.1016\/j.ando.2022.12.424_bib0365","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12022-007-9006-y","article-title":"P53 Gene mutations in pituitary carcinomas","volume":"18","author":"Tanizaki","year":"2007","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ando.2022.12.424_bib0370","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J Clin. Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0375","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3389\/fonc.2018.00510","article-title":"Identification of novel genes involved in the pathogenesis of an acth-secreting pituitary carcinoma: a case report and literature review","volume":"8","author":"Guo","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0380","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"key":"10.1016\/j.ando.2022.12.424_bib0385","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ando.2022.12.424_bib0395","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ando.2022.12.424_bib0400","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2017.07.011","article-title":"Epigenetics of pituitary tumors: pathogenetic and therapeutic implications","volume":"469","author":"Ezzat","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ando.2022.12.424_bib0405","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1530\/EO-22-0041","article-title":"Pituitary carcinoma: reclassification and implications in the NET schema","volume":"2","author":"Asa","year":"2022","journal-title":"Endocr Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0410","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/epi-2021-0165","article-title":"The role of noncoding RNAs in pituitary adenoma","volume":"13","author":"Bahreini","year":"2021","journal-title":"Epigenomics"},{"key":"10.1016\/j.ando.2022.12.424_bib0415","first-page":"OC7.5","article-title":"Epigenomic and somatic mutation profile of pituitary adenomas (PAs)\/pituitary neuroendocrine tumors (PitNETs)","volume":"81","author":"Guaraldi","year":"2022","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ando.2022.12.424_bib0420","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ando.2022.12.424_bib0425","doi-asserted-by":"crossref","first-page":"596554","DOI":"10.3389\/fendo.2020.596554","article-title":"Genetic and epigenetic causes of pituitary adenomas","volume":"11","author":"Chang","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2022.12.424_bib0430","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers11101605","article-title":"The microenvironment of pituitary tumors\u2013biological and therapeutic implications","volume":"11","author":"Ilie","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ando.2022.12.424_bib0435","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s12020-020-02478-z","article-title":"The role of the tumour microenvironment in the angiogenesis of pituitary tumours","volume":"70","author":"Marques","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2022.12.424_bib0440","series-title":"Recent Adv Prolactin Res","first-page":"265","article-title":"A positive feedback loop between prolactin and stat5 promotes angiogenesis","author":"Yang","year":"2015"},{"key":"10.1016\/j.ando.2022.12.424_bib0445","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1210\/jc.2017-01000","article-title":"Growth hormone and the epithelial-to-mesenchymal transition","volume":"102","author":"Brittain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0450","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12672-017-0307-4","article-title":"Inhibitory effects of antagonists of growth hormone-releasing hormone (GHRH) in thyroid cancer","volume":"8","author":"P\u00f3pulo","year":"2017","journal-title":"Horm Cancer"},{"key":"10.1016\/j.ando.2022.12.424_bib0455","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/pros.23648","article-title":"Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer","volume":"78","author":"Mu\u00f1oz-Moreno","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ando.2022.12.424_bib0460","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1073\/pnas.180313297","article-title":"Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers","volume":"97","author":"Rekasi","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ando.2022.12.424_bib0465","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/cancers14143481","article-title":"Reciprocal interactions between fibroblast and pancreatic neuroendocrine tumor cells: putative impact of the tumor microenvironment","volume":"14","author":"Cuny","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ando.2022.12.424_bib0470","doi-asserted-by":"crossref","first-page":"e220093","DOI":"10.1530\/EC-22-0093","article-title":"Systematic detection of mosaicism by using digital NGS reveals 3 new MEN1 mosaicisms","volume":"11","author":"Lagarde","year":"2022","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2022.12.424_bib0475","first-page":"381","article-title":"Unveiling the role and contribution of CELF4 to the malignant features of PanNETs","volume":"81","author":"Garcia","year":"2022","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ando.2022.12.424_bib0480","first-page":"381","article-title":"Granin family peptides and INSM-1 (Insulinoma-associated protein 1) in the biochemical diagnosis of pheochromocytoma","volume":"81","author":"Glinicki","year":"2022","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ando.2022.12.424_bib0485","doi-asserted-by":"crossref","first-page":"e2662","DOI":"10.1210\/clinem\/dgac207","article-title":"Molecular imaging of neuroendocrine neoplasms","volume":"107","author":"Refardt","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0490","doi-asserted-by":"crossref","first-page":"e3953","DOI":"10.1210\/clinem\/dgac298","article-title":"Functional imaging of neuroendocrine tumors: stacking the odds in a patient's favor","volume":"107","author":"Pacak","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0495","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/ijms23052413","article-title":"Overexpression of miR-375 and L-type amino acid transporter 1 in pheochromocytoma and their molecular and functional implications","volume":"23","author":"Manso","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ando.2022.12.424_bib0500","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41571-021-00495-z","article-title":"Precision oncology in metastatic colorectal cancer\u2013from biology to medicine","volume":"18","author":"Di Nicolantonio","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0505","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0510","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0515","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12672-021-00404-x","article-title":"Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion","volume":"12","author":"Li","year":"2021","journal-title":"Discov Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0520","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2022.12.424_bib0525","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2022.12.424_bib0530","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2022.12.424_bib0535","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel\u2013lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2022.12.424_bib0540","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/j.annonc.2021.08.702","article-title":"567O First international randomized study in malignant progressive pheochromocytoma and paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0545","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2022.12.424_bib0550","unstructured":"A. Boil\u00e8ve, M. Faron, S. Fodil-Ch\u00e9rif, A. Bayle, L. Lamartina, D. Planchard, L. Tselikas, J.-Y. Scoazec, M. Ducreux, A. Italiano, E. Baudin, J. Hadoux. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: the Gustave Roussy experience, Submitted. (n.d.)."}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:14Z","timestamp":1757717654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0003426623000082"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2022.12.424","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in neuroendocrine neoplasms: From mechanisms to the clinic","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2022.12.424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}